FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) and PharmAthene, Inc. have entered into an agreement under which GTC will provide process development and clinical supply manufacturing services for PharmAthene’s Protexia® program. Protexia® is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats, which is being developed by PharmAthene as a pre- and post-exposure therapy for military or civilian victims of a chemical nerve agent attack.
